NCNA NuCana plc ADRs

NuCana PLC is a clinical-stage biopharmaceutical company. It is focused on improving treatment outcomes for cancer patients by applying its ProTide technology. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$2.60  -0.09 (-3.17%)
As of 10/19/2021 15:59:50 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  09/28/2017
Outstanding shares:  52,162,044
Average volume:  5,229,827
Market cap:   $139,272,657
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    67022C106
ISIN:        US67022C1062
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.77
PS ratio:   0.00
Return on equity:   -46.92%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy